at the representative endpoint of 1.5 h. e reperfusion time non-signifi cantly decreased the SUA levels by 13.61%±9.18% (p=0.126) 15,43%±9,10% (p=0,096). Reperfuzija nije dovela do statistički značajnog smanjenja nivoa mokraćne kiseline u serumu 13,61%±9,18% (p=0,126 15,43%±9,10% (p=0,096). Reperfuzija nije dovela do statistički značajnog smanjenja nivoa mokraćne kiseline u serumu 13,61%±9,18% (p=0,126). Bez obzira na reperfuziono vreme administracija U-74389G nije statistički značajno povisila nivo mokraćne kiseline u serumu. Izgleda da u toku dva sata U-74389G ne može popraviti povredu tubularnih epitelijalnih ćelija nastalu ishemijom i reperfuzijom.
SAŽETAK

U ovoj eksperimentalnoj studiji ispitivani su efekti antioksidacionog leka U-74389G tokom ishemije i reperfuzije bubrega na modelu pacova. Efekti ispitivanog molekula su izučavani biohemijski, merenjem srednje vrednosti nivoa mokraćne kiseline u serumu. U studiji je korišćeno 40 pacova (prosečna telesna masa= 231,875g). Nivoi mokraćne kiseline u serumu su mereni za grupe A i C u šezdesetom minutu, a za grupe B i D u stodvadesetom minutu reperfuzije. U-74389G je primenjivan samo u grupi C i D. Administracija U-74389G nije dovela do statistički značajnog poveća-nja niova mokraćne kiseline u krajnjoj tački u devedesetom minutu 15,43%±9,10% (p=0,096). Reperfuzija nije dovela do statistički značajnog smanjenja nivoa mokraćne kiseline u serumu 13,61%±9,18% (p=0,126). Bez obzira na reperfuziono vreme administracija U-74389G nije statistički značajno povisila nivo mokraćne kiseline u serumu. Izgleda da u toku dva sata U-74389G ne može popraviti povredu tubularnih epitelijalnih ćelija nastalu ishemijom i reperfuzijom.
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ABBREVIATIONS
IR -ischaemia-reperfusion
SUA -serum uric acid SD -standard deviation L -lazaroid GLM -generalized linear models AIS -acute ischaemic stroke mental housing allowed for an ad libitum diet in the laboratory. In total, 40 female albino Wistar rats (16 -18 weeks old) were used (mean weight ± standard deviation (SD): 232±37 g), with a minimum weight of 165 g and a maximum weight of 320 g. Rats' weights could be a confounding factor; e.g., more obese rats have higher SUA levels. This was also investigated. Post-experimental awakening of animals was not permitted, even if euthanasia was needed. Rats were randomly sorted into four experimental groups with 10 animals in each group using the following IR protocols: ischemia for 45 min followed by reperfusion for 60 min (group A); ischaemia for 45 min followed by reperfusion for 120 min (group B); ischaemia for 45 min followed by immediate U-74389G intravenous (IV) administration and reperfusion for 60 min (group C); and ischaemia for 45 min followed by immediate U-74389G IV administration and reperfusion for 120 min (group D). The dose of U-74389G was 10 mg/kg body mass. The protocol and doses were determined via the following experiments with favourable outcomes. Flessas I et al. found (5) that the role of U-74389G was protective in many emergency clinical situations of intestinal IR. Bimpis A et al. showed limited brain damage after (6) U-74389G administration. Tsaroucha AK et al. (7) showed attenuated liver damage after U-74389G administration. Andreadou I et al. showed that the small intestine (8) was protected after U-74389G administration.
The detailed prenarcotic and general anaesthesiologic techniques were described previously (3, 4) . A continuous intra-experimental oxygen supply, electrocardiogram and acidometry were maintained. Ischaemia was caused by laparotomic clamping of the inferior aorta over the renal arteries with forceps for 45 min. Reperfusion was induced by removing the clamp and re-establishing the patency of the inferior aorta. After the exclusion of a blood flow, the IR protocol was applied as described above for each experimental group. U-74389G was administered at the time of reperfusion through the catheterized inferior vena cava. The SUA levels were determined at the 60th min of reperfusion (for the A and C groups) and at the 120th min of reperfusion (for the B and D groups).
Control groups
Twenty control rats (252±39 g) underwent ischaemia for 45 min followed by reperfusion.
Group A Reperfusion lasted for 60 min (n=10 control rats, 243±46 g), and SUA levels were 1.03±0.176 mg/dl (Table 1) .
Group B Reperfusion lasted for 120 min (n=10 control rats, 262±31 g), and SUA levels were 0.95±0.295 mg/dl (Table 1) .
Groups receiving the lazaroid (L) drug U-74389G
The 20 rats (211+17 g) receiving L experienced ischaemia for 45 min followed by reperfusion after 10 mg of U-74389G /kg body weight was IV administered.
INTRODUCTION
Tissue ischaemia-reperfusion (IR) injury can induce permanent or transient damage with serious implications to adjacent organs and systems. The use of U-74389G in IR has been a challenge for many years. However, although progress has been significant, several practical questions have not been clarified. They include: a) how potent U-74389G should be; b) when it should be administered; and c) the optimal dose at which U-74389G should be administered.
The promising effect of U-74389G in tissue protection has been noted in several IR studies. U-74389G, also known as 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione maleate salt, is an antioxidant that prevents both arachidonic acidinduced and iron-dependent lipid peroxidation (1). Lazaroids, a novel series of glucocorticoid compounds such as 21-aminosteroids, promote free radical scavenging. U-74389G is one of the 132 similar lazaroid compounds. It has a molecular weight of 726.90406 g/mol and a selective action on vascular endothelium with vitamin E-like properties. It also exhibits neuroprotection and membrane-stabilizing properties. It protected against IR injury in heart, liver and kidney models. These membrane-associated antioxidants are particularly effective in preventing permeability changes in monolayers of brain microvascular endothelial cells (2) . A meta-analysis of 15 published studies, including red blood cell counts, haemoglobin and mean corpuscular haemoglobin levels, platelet count, plateletcrit, platelet distribution width, glucose, total protein, alkaline phosphatase, creatine phosphokinase, sodium, chloride, calcium, phosphorus and magnesium levels, examined in the same experimental setting, provided a total numeric evaluation of the U-74389G anabolic efficacy of approximately +2.14%±7.18% (p-value = 0.227) at the same endpoints (3, 4) . Several publications addressed trials of other similar antioxidant molecules to which the studied molecule U-74389G belongs.
The aim of this experimental study was to evaluate the effect of U-74389G in a rat model of renal IR using mean serum uric acid levels (SUA).
MATERIALS AND METHODS
Animal preparation
This basic experimental study was licensed by Veterinary Address of East Attiki Prefecture under 3693/12-11-2010 & 14/10-1-2012. All consumables, equipment and substances used were grants of the Experimental Research Centre of ELPEN Pharmaceuticals Co. Inc. S.A. at Pikermi, Attiki. Accepted standards of humane animal care were adopted for albino female Wistar rats. Seven days of normal pre-experi-liver, where most of it is converted to uric acid. Lazzarino G et al. found (13) significantly increased levels of SUA after cerebral IR in rats.
Although SUA predicts AIS and leads to gout, how renal SUA excretion is influenced by U-74389G is unknown. Moreover, only reperfusion time resulted in a non-significant decline of SUA levels, reflecting a non-significant increase in renal SUA excretion. All the other endpoints implicated by U-74389G administration exhibited discouraging but non-significant results. U-74389G increased SUA levels, reflecting a decrease in renal SUA excretion. This may stand for a generalized lack of amelioration of renal function by U-74389G administration. U-74389G Group C Reperfusion lasted for 60 min (n=10 L rats, 212±17 g), and SUA levels were 1.27±0.457 mg/dl (Table 1) .
Group D Reperfusion lasted for 120 min (n=10 L rats, 210±18 g), and SUA levels were 1.05±0.201 mg/dl (Table 1) .
STATISTICAL ANALYSIS
Every weight and SUA level group was compared with each other using paired t-tests. Significant differences among SUA levels were investigated. A generalized linear model (GLM) was applied with SUA levels as the dependent variable. The 3 independent variables were: the presence/absence of U-74389G, the reperfusion time, and both variables in combination. Using rat weight as an independent variable in the GLM analysis, a non-significant relationship was detected (p=0.4431), so further investigation was not needed.
RESULTS
The application of GLM resulted in the following findings: U-74389G administration non-significantly in 
DISCUSSION
SUA is considered to be a reliable index of renal function. Its production is influenced by ischaemia and by a certain mode. Chiquete E et al. showed (9) that SUA is a potent antioxidant, and its serum concentration increases rapidly after acute ischaemic stroke (AIS). They associated the magnitude of cerebral infarction with the mean SUA concentration and favourable outcomes (p = 0.004) in patients with AIS upon hospital arrival. Logallo N et al. positively correlated (10) the adjusted SUA level with clinical improvement (p = 0.02) and favourable stroke outcome (p = 0.04) in patients with tissue plasminogen activator thrombolysis upon admission. Seifert J et al. found (11) SUA levels on day 7 and ribose ingestion after 14 days. Hellsten-Westing Y et al. found (12) that SUA is taken up by the strenuous muscle, which is the main source of plasma hypoxanthine in the blood. SUA is also taken up by the 
CONCLUSION
Whether it interacted with reperfusion time, U-74389G administration non-significantly increased SUA levels. U-74389G cannot reverse injury to IR tubular epithelial cells within 2 hours. Perhaps either a longer study time or a higher U-74389G dosage may reverse tubular apoptosis and prevent acute tubular necrosis.
